CA
NZ
UK
AU
IND
US
…
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company listed on NASDAQ that develops therapeutic candidates and reports progress through regulatory and clinical disclosures. Long-term growth may be driven by positive clinical trial outcomes, successful regulatory milestones and licensing or commercialization agreements that could support revenue generation. The company may appeal to investors seeking pipeline-driven upside and near-term event catalysts.
Key risks include high probability of clinical or regulatory setbacks, ongoing cash burn that may require additional dilutive financing, and significant share-price volatility typical of small-cap biotech issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
| Net income | -57.44M | -44.60M | -40.42M | -64.81M | -47.13M |
| Selling general administrative | 21.92M | 17.45M | 18.62M | 20.74M | 26.40M |
| Selling and marketing expenses | - | - | 0.14M | - | - |
| Gross profit | -0.36M | -0.33M | -0.34M | - | - |
| Reconciled depreciation | 0.36M | 0.33M | 0.31M | 0.25M | 0.12M |
| Ebit | -57.44M | -44.60M | -40.42M | -67.06M | -47.49M |
| Ebitda | -57.08M | -44.26M | -40.08M | -8.03M | -47.25M |
| Depreciation and amortization | 0.36M | 0.33M | 0.34M | 59.03M | 0.24M |
| Operating income | -64.55M | -49.15M | -43.61M | -67.06M | -47.49M |
| Other operating expenses | 64.55M | 49.15M | 43.61M | 37.55M | 47.49M |
| Interest expense | - | 4.17M | - | 1.14M | 1.74M |
| Interest income | 6.33M | 4.13M | 3.00M | 2.23M | 1.97M |
| Net interest income | 6.33M | 4.13M | 2.89M | 1.09M | 0.24M |
| Income tax expense | - | - | -0.34M | -1.14M | -0.12M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 64.19M | 49.15M | 43.27M | 37.55M | 47.49M |
| Cost of revenue | 0.36M | 0.33M | 0.34M | - | - |
| Total other income expense net | 7.11M | 4.56M | 3.19M | 1.11M | 0.24M |
| Net income from continuing ops | -57.44M | -44.60M | -69.17M | -65.95M | -47.25M |
| Net income applicable to common shares | - | - | - | -65.95M | -47.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Intangible assets | 2.93M | 3.25M | - | - | - |
| Other current assets | 2.69M | 1.86M | 2.88M | 0.13M | 0.03M |
| Total liab | 13.06M | 14.32M | 10.63M | 11.21M | 10.68M |
| Total stockholder equity | 196.41M | 167.13M | 68.32M | 102.08M | 161.91M |
| Other current liab | 6.23M | 5.41M | 2.73M | 3.24M | 2.49M |
| Common stock | 0.05M | 0.04M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.05M | 0.04M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -302.42M | -244.98M | -200.38M | -159.96M | -94.01M |
| Good will | - | - | - | 0.00M | 29.52M |
| Other assets | - | - | 0.00M | 1.39M | 1.61M |
| Cash | 49.66M | 162.80M | 39.59M | 24.13M | 35.72M |
| Total current liabilities | 10.94M | 10.96M | 6.15M | 5.74M | 4.30M |
| Net debt | -46.30M | -158.31M | -34.12M | -17.74M | -28.48M |
| Short term debt | 1.24M | 1.12M | 0.98M | 0.92M | 0.85M |
| Short long term debt total | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Other stockholder equity | 498.69M | 412.08M | 268.73M | 262.72M | 256.13M |
| Property plant equipment | - | - | - | 7.87M | 8.89M |
| Total current assets | 159.50M | 172.16M | 68.70M | 86.15M | 93.11M |
| Long term investments | 42.34M | 0.00M | 0.00M | 17.89M | 39.47M |
| Net tangible assets | - | - | - | 102.08M | 132.40M |
| Short term investments | 105.90M | 7.49M | 25.99M | 60.24M | 55.51M |
| Net receivables | 1.26M | - | 0.24M | 0.49M | 0.63M |
| Inventory | - | - | - | 1.16M | 1.22M |
| Accounts payable | 3.47M | 4.43M | 2.43M | 1.59M | 0.95M |
| Accumulated other comprehensive income | 0.09M | 0.00M | -0.03M | -0.69M | -0.21M |
| Non currrent assets other | 0.77M | 0.77M | 2.94M | 1.39M | 1.61M |
| Non current assets total | 49.96M | 9.30M | 10.25M | 27.14M | 79.48M |
| Capital lease obligations | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -139.40M | 19.16M | 20.24M | 14.95M | -97.60M |
| Change to liabilities | - | - | - | 0.63M | 0.04M |
| Total cashflows from investing activities | -139.49M | 19.16M | 53.11M | 14.95M | -98.19M |
| Total cash from financing activities | 82.72M | 139.87M | -0.09M | -0.09M | -0.23M |
| Change to operating activities | - | - | - | -0.09M | -0.56M |
| Net income | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
| Change in cash | -113.14M | 123.21M | 15.46M | -11.60M | -132.92M |
| Begin period cash flow | 163.54M | 40.33M | 24.87M | 36.47M | 169.39M |
| End period cash flow | 50.40M | 163.54M | 40.33M | 24.87M | 36.47M |
| Total cash from operating activities | -56.37M | -35.81M | -37.56M | -26.46M | -34.50M |
| Issuance of capital stock | 80.96M | 136.01M | 0.00M | - | 0.00M |
| Depreciation | 0.36M | 0.33M | 0.34M | 0.25M | 0.12M |
| Sale purchase of stock | - | - | -0.09M | -0.09M | -0.23M |
| Other cashflows from financing activities | -0.18M | 3.86M | 53.11M | 14.95M | -98.19M |
| Change to netincome | - | - | - | 38.71M | 12.10M |
| Capital expenditures | 0.09M | 0.06M | 0.04M | 0.12M | 0.60M |
| Change in working capital | -2.94M | 4.01M | -4.14M | 0.54M | 0.53M |
| Stock based compensation | 3.83M | 4.12M | 6.09M | 6.69M | 10.36M |
| Other non cash items | -0.17M | 0.32M | 0.57M | 32.02M | 1.74M |
| Free cash flow | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics Inc |
0.19 7.82% |
2.62 | - | - | - | 1.44 | 0.74 |
| NVO Novo Nordisk A/S |
0.41 1.00% |
41.10 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.86 0.16% |
547.03 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
43.35 4.73% |
959.41 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jesse Shefferman | Co-Founder, Principal Financial Officer, CEO, Pres & Director | 1972 |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Sr. VP & Chief Scientific Operations Officer | 1981 |
| Ms. Hannah Fry | Principal Accounting Officer & Controller | 1990 |
| Ms. Justine O'Malley | Sr. VP of Investor Relations & Corp. Affairs | NA |
| Ms. Mary J. Grendell | Gen. Counsel & Corp. Sec. | NA |
| Ms. Kristine Rosse | Sr. VP & Chief People Officer | NA |
| Dr. Jathin Bandari M.D. | Chief Medical Officer | NA |
| Mr. Jesse Shefferman | Co-Founder, CEO, President & Director | 1972 |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior VP & Chief Scientific Operations Officer | 1981 |
| Dr. Jathin Bandari M.D. | Executive Officer | 1988 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.29%
Communication Services
+0.51%
Consumer Cyclical
-0.08%
Consumer Defensive
-0.14%
Energy
+1.08%
Financial Services
+0.14%
Financials
-0.06%
Healthcare
+0.51%
Industrials
+0.47%
Real Estate
-0.23%
Technology
+2.03%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...